LifeStance Health Group, Inc. $LFST Shares Bought by Versor Investments LP

Key Points

• Versor Investments LP significantly increased its stake in LifeStance Health Group by 1,113.5%, owning 216,000 shares valued at approximately $1.44 million after purchasing an additional 198,200 shares.
• LifeStance Health Group's stock has received positive ratings, with UBS Group raising its price target from $8.50 to $9.00 and several analysts issuing a "buy" rating.
• In the most recent earnings report, LifeStance Health Group reported a revenue of $345.31 million, exceeding expectations and reflecting a 10.6% year-over-year increase despite a slight net loss.

Versor Investments LP lifted its stake in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 1,113.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 216,000 shares of the company's stock after purchasing an additional 198,200 shares during the period. Versor Investments LP owned approximately 0.06% of LifeStance Health Group worth $1,439,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Choreo LLC raised its position in LifeStance Health Group by 6.4% during the first quarter. Choreo LLC now owns 27,420 shares of the company's stock worth $183,000 after acquiring an additional 1,661 shares during the last quarter. LPL Financial LLC raised its position in LifeStance Health Group by 6.0% during the fourth quarter. LPL Financial LLC now owns 37,584 shares of the company's stock worth $277,000 after acquiring an additional 2,127 shares during the last quarter. Invesco Ltd. raised its position in LifeStance Health Group by 1.4% during the first quarter. Invesco Ltd. now owns 164,384 shares of the company's stock worth $1,095,000 after acquiring an additional 2,238 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of LifeStance Health Group by 2.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 138,781 shares of the company's stock worth $1,023,000 after buying an additional 3,305 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of LifeStance Health Group during the first quarter worth about $31,000. Institutional investors and hedge funds own 85.50% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently commented on LFST. Wall Street Zen upgraded shares of LifeStance Health Group from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. BTIG Research began coverage on shares of LifeStance Health Group in a report on Friday, July 25th. They set a "buy" rating and a $8.00 price target for the company. Finally, UBS Group lifted their price target on shares of LifeStance Health Group from $8.50 to $9.00 and gave the stock a "buy" rating in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, LifeStance Health Group currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.50.

LifeStance Health Group Trading Up 0.9%

LFST traded up $0.05 during trading on Friday, hitting $5.55. 2,992,296 shares of the company's stock were exchanged, compared to its average volume of 2,022,111. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.19. LifeStance Health Group, Inc. has a 1 year low of $3.74 and a 1 year high of $8.61. The stock has a 50 day moving average price of $4.67 and a 200 day moving average price of $6.02. The firm has a market cap of $2.16 billion, a P/E ratio of -111.00 and a beta of 1.13.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The business had revenue of $345.31 million for the quarter, compared to analysts' expectations of $345.05 million. During the same period in the previous year, the company posted ($0.06) earnings per share. The business's revenue for the quarter was up 10.6% compared to the same quarter last year. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts expect that LifeStance Health Group, Inc. will post -0.18 EPS for the current fiscal year.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, Director Darren M. Black sold 8,407,643 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the sale, the director directly owned 33,524,715 shares of the company's stock, valued at approximately $169,970,305.05. This represents a 20.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Silversmith Partners I. Gp, Llc sold 3,592,357 shares of the company's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.07, for a total transaction of $18,213,249.99. Following the transaction, the insider owned 14,324,197 shares of the company's stock, valued at $72,623,678.79. This represents a 20.05% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,423,643 shares of company stock valued at $103,561,790. Insiders own 3.20% of the company's stock.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.